IL327385A - מעכבי rock2 בטיפול בהשמנה - Google Patents

מעכבי rock2 בטיפול בהשמנה

Info

Publication number
IL327385A
IL327385A IL327385A IL32738526A IL327385A IL 327385 A IL327385 A IL 327385A IL 327385 A IL327385 A IL 327385A IL 32738526 A IL32738526 A IL 32738526A IL 327385 A IL327385 A IL 327385A
Authority
IL
Israel
Prior art keywords
obesity
treatment
rock2 inhibitors
rock2
inhibitors
Prior art date
Application number
IL327385A
Other languages
English (en)
Original Assignee
Graviton Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graviton Pharmaceuticals B V filed Critical Graviton Pharmaceuticals B V
Publication of IL327385A publication Critical patent/IL327385A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL327385A 2023-09-29 2024-09-30 מעכבי rock2 בטיפול בהשמנה IL327385A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363586921P 2023-09-29 2023-09-29
PCT/IB2024/059568 WO2025069009A1 (en) 2023-09-29 2024-09-30 Rock2 inhibitors in the treatment of obesity

Publications (1)

Publication Number Publication Date
IL327385A true IL327385A (he) 2026-05-01

Family

ID=93257864

Family Applications (1)

Application Number Title Priority Date Filing Date
IL327385A IL327385A (he) 2023-09-29 2024-09-30 מעכבי rock2 בטיפול בהשמנה

Country Status (3)

Country Link
AU (1) AU2024352974A1 (he)
IL (1) IL327385A (he)
WO (1) WO2025069009A1 (he)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005723A1 (fr) 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6127263A (en) 1998-07-10 2000-10-03 Applied Materials, Inc. Misalignment tolerant techniques for dual damascene fabrication
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
AU2001273233A1 (en) 2000-07-06 2002-01-21 Deltagen, Inc. Transgenic mice containing cx2 gene disruptions
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
JP4764823B2 (ja) 2003-10-06 2011-09-07 グラクソ グループ リミテッド キナーゼ阻害剤としての１，６−二置換アザベンゾイミダゾールの調製
JP4857128B2 (ja) 2004-02-20 2012-01-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規な化合物
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
PL1905452T3 (pl) 2005-07-12 2013-11-29 Kowa Co Środek do zapobiegania lub leczenia jaskry
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
EP2406236A4 (en) * 2009-03-09 2013-07-24 Surface Logix Inc RHO KINASE INHIBITORS
WO2011130740A2 (en) 2010-04-16 2011-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
EP2903618B1 (en) 2012-10-05 2022-06-01 Kadmon Corporation, LLC Rho kinase inhibitors
WO2015157556A1 (en) 2014-04-09 2015-10-15 Kadmon Corporation, Llc Treatment of gvhd
JO3575B1 (ar) 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
AU2020273376C1 (en) * 2016-10-24 2024-02-29 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
CN110325530B (zh) 2016-12-16 2022-01-11 辉瑞大药厂 Glp-1受体激动剂及其用途
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
AU2018294054B2 (en) 2017-06-30 2022-05-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
CN110573501B (zh) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
WO2019194598A1 (ko) * 2018-04-05 2019-10-10 서울대학교산학협력단 비만 및 당뇨 개선을 위한 골격근 대사 활성화제로서의 rock2 억제제
WO2020142745A1 (en) * 2019-01-04 2020-07-09 Translational Drug Development, Llc Methods of treating graft versus host disease and neoplastic disease with amide compounds
US12398118B2 (en) 2018-11-09 2025-08-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof
KR102906316B1 (ko) 2019-03-01 2025-12-31 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 지방간 질환 및/또는 지방간염의 치료 방법
CA3144113A1 (en) 2019-06-25 2020-12-30 Beijing Tide Pharmaceutical Co., Ltd. Method for treating idiopathic pulmonary fibrosis
CA3168543A1 (en) * 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
CN118772118A (zh) 2020-08-31 2024-10-15 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
KR20230058466A (ko) 2020-08-31 2023-05-03 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 신규한 rho-연관 단백질 인산화효소 억제제의 제조 방법 및 제조 방법 중의 중간체
US20220193063A1 (en) 2020-12-15 2022-06-23 Pfizer Inc. Metabolites of glp1r agonists
WO2022192430A1 (en) * 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
US20220348564A1 (en) 2021-03-24 2022-11-03 Eccogene (Shanghai) Co., Ltd. Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
US11779588B2 (en) * 2021-10-15 2023-10-10 Woolsey Pharmaceuticals, Inc. Method of treating amyotrophic lateral sclerosis
US20250289807A1 (en) 2022-04-29 2025-09-18 Graviton Bioscience Bv Inhibitors of ROCK2
AU2023386016A1 (en) 2022-11-21 2025-06-19 Graviton Bioscience Bv Inhibitors of rock2

Also Published As

Publication number Publication date
AU2024352974A1 (en) 2026-05-14
WO2025069009A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
IL308195A (he) מעכבי ras לטיפול בסרטן
PT4181920T (pt) Inibidor de kat6 e combinações para o tratamento do cancro da mama
IL288395A (he) מעכבים הטרוביציקליים של mat2a ושיטות לשימוש לטיפול בסרטן
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
IL307883A (he) מעכבי hdac6 לשימוש בטיפול במחלת שריר הלב מורחבת
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
IL310209A (he) מעכבי rock2 ושימושים שלהם
IL289758A (he) מעכבי פרופורטין לשימוש במניעה וטיפול בפגיעות בכליות
IL316829A (he) מעכבי מנין-mll לטיפול בסרטן
IL276668A (he) מעכבי תירודוקסין רדוקטאז לשימוש בטיפול בסרטן
IL321393A (he) מעכבי ctps1 לשימוש בטיפול בסרטן עם חוסר ב- ctps2
SMT202500434T1 (it) Sotorasib per l'uso nel trattamento del cancro
SI3969000T1 (sl) Bcl-2 inhibitorji za uporabo pri zdravljenju z Bcl-2 posredovanega raka, ki nosi mutacijo Gly101Val
EP4193995A4 (en) USE OF BTK INHIBITORS TO TREAT DISEASES
AU2024352974A1 (en) Rock2 inhibitors in the treatment of obesity
CA3305450A1 (en) Rock2 inhibitors in the treatment of obesity
IL318816A (he) MTA-COOPERATIVE PRMT5 inhibitors לשימוש בטיפול בסרטן
PL4346847T3 (pl) Kompleks wielojonowy do stosowania w profilaktyce lub leczeniu zapalenia neurogennego
IL319049A (he) מעכבי tyk2 ושימושים בהם
GB202002299D0 (en) Agents for use in the treatment of tissue damage
HK40090075A (en) Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies
IL290328A (he) מעכבי מונואמין אוקסידאז b לשימוש במניעה או טיפול בגידול ממאיר בערמונית
IL327100A (he) אלסונרסן/ prax-22לשימוש בטיפול בהפרעות הקשורות ל scn2a-
HK40081983A (en) Cxcl8 inhibitors for use in the treatment of covid-19
IL319889A (he) טיפול משולב במעכב סי.וואי.פי.2.די.6 וטספימידין